Appraising the mitogenicity of insulin analogues relative to human insulin - Response to: Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H. Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activity in cultured cancer cells. Diabetes Metab Res Rev 2009; 25(1): 41-9

Diabetes/Metabolism Research and Reviews

Volumn 26, Issue 3, 2010, Pages 145-149

  Kazda, C ^a   Slieker, L ^a   Ilag, L ^a   Byrd, R ^a   Rees, T ^a   Prince, M ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

In vitro; Insulin lispro; Mitogenicity

Indexed keywords

HUMAN INSULIN; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

CANCER CELL CULTURE; HUMAN; HUMAN CELL; MITOGENICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PRIORITY JOURNAL;

APOPTOSIS; CELL DIVISION; CELL LINE, TUMOR; HUMANS; INSULIN;

EID: 77952339963     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1072     Document Type: Note

References (31)

1. Slieker LJ, Brooke GS, DiMarchi RD, et al. Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor. Diabetologia 1997; 40(Suppl 2): S54-S61.
2. Sandow J. Growth effects of insulin and insulin analogues. Arch Physiol Biochem 2009; 115(2): 72-85. DOI: 10.1080/13813450902835690.
3. Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009; 52(9): 1732-1744. DOI: 10.1007/s00125-009-1418-4.
4. Colhoun HM. SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009; 52(9): 1755-1765. DOI: 10.1007/s00125-009-1453-1.
5. Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdò ttir S, Steineck G. Insulin glargine use and short-term incidence of malignancies-population-based follow-up study in Sweden. Diabetologia 2009; 52(9): 1745-1754. DOI: 10.1007/s00125-009-1444-2.
6. Dejgaard A, Lynggaard H, Råstam J, Krogsgaard Thomsen M. No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis. Diabetologia 2009; 52(12): 2507-2512. DOI: 10.1007/s00125-009-1568-4.
7. Home PD, Lagarenne P. Combined randomized controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 2009; 52(12): 2499-2506. DOI: 10.1007/s00125-009-1530-5.
8. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 2007; 121(4): 856-862. DOI: 10.1002/ijc.22717. (Pubitemid 47106217)
9. Larsson SC, Orsini N, Brismar K, Wolk A. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 2006; 49(12): 2819-2823. DOI: 10.1007/s00125-006-0468-0.
10. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 2005; 97(22): 1679-1687. DOI: 10.1093/jnci/dji375. (Pubitemid 41672234)
11. Stattin P, Björ O, Ferrari P, et al. Prospective study of hyperglycemia and cancer risk. Diabetes Care 2007; 30(3): 561-567. DOI: 10.2337/dc06-0922. (Pubitemid 46354334)
12. Kim YI. Diet, lifestyle, and colorectal cancer: is hyperinsulinemia the missing link? Nutr Rev 1998; 56(9): 275-279.
13. Werner H, Bruchim I. The insulin-like growth factor-I receptor as an oncogene. Arch Physiol Biochem 2009; 115(2): 58-71. DOI: 10.1080/ 13813450902783106.
14. Morrione A, DeAngelis T, Baserga R. Failure of the bovine papillomavirus to transform mouse embryo fibroblasts with a targeted disruption of the insulin-like growth factor I receptor genes. J Virol 1995; 69(9): 5300-5303.
15. Allen NE, Roddam AW, Allen DS, et al. A prospective study of serum insulin-like growth factor-I (IGF-I), IGF-II, IGF-binding protein-3 and breast cancer risk. Br J Cancer 2005; 92(7): 1283-1287. DOI: 10.1038/sj.bjc.6602471.
16. Palmqvist R, Hallmans G, Rinaldi S, et al. Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: a prospective study in northern Sweden. Gut 2002; 50(5): 642-646.
17. Zhao H, Grossman HB, Spitz MR, Lerner SP, Zhang K, Wu X. Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer risk. J Urol 2003; 169(2): 714-717. DOI: 10.1097?01.ju. 0000036380.10325.2a.
18. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004; 363(9418): 1346-1353.
19. Kurtzhals P, Schäffer L, Sørensen A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000; 49(6): 999-1005.
20. Smith U, Gale EAM. Does diabetes therapy influence the risk of cancer? Diabetologia 2009; 52(9): 1699-1708. DOI: 10.1007/s00125-009-1441-5.
21. Eckardt K, May C, Koenen M, Eckel J. IGF-1 receptor signalling determines themitogenic potency of insulin analogues in human smooth muscle cells and fibroblasts. Diabetologia 2007; 50(12): 2534-2543. DOI: 10.1007/s00125-007-0815- 9.
22. Mayer D, Shukla A, Enzmann H. Proliferative effects of insulin analogues on mammary epithelial cells. Arch Physiol Biochem 2008; 114(1): 38-44. DOI: 10.1080/13813450801900645.
23. Jørgensen LN, Dideriksen LH, Drejer K. Carcinogenic effect of the human insulin analogue B10 Asp in female rats (abstract). Diabetologia 1992; 35(Suppl 1): A3.
24. Shukla A, Enzmann H, Mayer D. Proliferative effect of Apdira® (insulin glulisine), a rapid-acting insulin analogue on mammary epithelial cells. Arch Physiol Biochem 2009; 115(3): 119-126. DOI: 10.1080/ 13813450903008628.
25. Zimmerman JL, Truex LL. 12-month chronic toxicity study of LY275585 (human insulin analog) administered subcutaneously to Fischer 344 rats. Int J Toxicol 1997; 16(6): 639-657.
26. Saegusa J, Yamaji S, Ieguchi I, et al. The direct binding of insulin-like growth factor-1 (IGF-1) to integrin alphavbeta3 is involved in IGF-1 signaling. J Biol Chem 2009; 284(36): 24106-24114. DOI: 10.1074/jbc.M109.013201.
27. Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H. Insulin analogs display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev 2009; 25(1): 41-49. DOI: 10.1002/dmrr.912.
28. Cordera R, Selani B, Briatore L. Insulin analogues: fears, facts, and fantasies. Diabetes Metab Res Rev 2009; 25(1): 50-51. DOI: 10.1002/dmrr.934.
29. Mattsson A, Svensson D, Schuett B, Osterziel KJ, Ranke MB. Multidimensional reference regions for IGF-I, IGFBP-2, and IGFBP-3 concentrations in serum of healthy adults. Growth Horm IGF Res 2008; 18(6): 506-516. DOI: 10.1016/j.ghir.2008.04.005.
30. Girard J. Normwerte. Available at: http://www.hormony.ch./fileadmin/ hormony docs/HormonNormwerte.pdf. Accessed December 4, 2009.
31. Heise T, Weyer C, Serwas A, et al. Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin. Diabetes Care 1998; 21(5): 800-803. DOI: 10.2337/diacare.21.5.800.